Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Halozyme Therapeutics (NasdaqGS:HALO) has appointed David Ramsay as Interim Chief Financial Officer. Ramsay, a former finance leader at the company with extensive biotechnology experience, will oversee financial operations during the search for a permanent CFO. The leadership change comes at a time when the company continues to manage growth initiatives and capital allocation priorities. For investors watching Halozyme Therapeutics, the CFO transition lands against a mixed share price backdrop. The stock closed at $63.66, with a 7 day return of a 5.5% decline and a 30 day return of a 17.2% decline, while the 3 year return stands at 92.4% and the 5 year return at 44.3%. That blend of recent weakness and longer term gains provides useful context as you consider how leadership decisions might relate to the company story. Ramsay's interim
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Halozyme Appoints David Ramsay as Interim Chief Financial OfficerPR Newswire
- Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 3/12/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 144
- HALO's page on the SEC website